Health Condition 1: L649- Androgenic alopecia, unspecified
Conditions
Interventions
Intervention1: INTRADERMAL INJECTION: Group A- Intradermal Injection Bicalutamide 0.5%
Participants will receive Injection Bicalutamide once monthly for 3 months.
1 ml of Injection Bicalutamide 0
Sponsors
Krishna Vishwa Vidyapeeth (Deemed to be University), karad
Eligibility
Inclusion criteria
Inclusion criteria: Inclusion criteria- Have given written consent before any treatment is commenced. Be diagnosed to be suffering from female patterned hair loss by assessment through LUDWIG scale clinically in dermatology OPD Have completed 18 years of age to 65 yrs of age Hair loss severity -women with grade 1 and 2 hair loss , as defined by Ludwig scale Women with polycystic ovarian syndrome (PCOS) not on hormonal therapy
Exclusion criteria
Exclusion criteria: Exclusion criteria- Following patient will be excluded from study- A. Age: Women under 18 years or over 65 years. B. Pregnancy or Lactation: Women who are pregnant, breastfeeding, or planning to become pregnant during the study period. C. Hormonal Imbalance: Women with hormonal imbalances, such as polycystic ovary syndrome (PCOS) on hormonal therapy, thyroid disorders, or adrenal disorders. D. Patient having keloid scaring or keloidal tendency. E. History of bleeding disorder and anticoagulant therapy. F. Oral steroid therapy. G. Active skin infection like warts, herpes and bacterial infection. H. Patient on any other systemic drugs therapy which in the judgement of investigator may interfere with interpretation of results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Change in hair density from baseline,4weeks ,8weeks, 12weeks,20weeks 2. change in hair thickness from baseline ,4weeks ,8weeks, 12weeks,20weeksTimepoint: 1.Change in hair density from baseline ,4weeks ,8weeks, 12weeks,20weeks 2. change in hair thickness from baseline ,4weeks ,8weeks, 12weeks,20weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary Outcome Variables Hair Growth Rate- Change in hair growth rate (mm/month) monthly from baseline to 6 months . Anagen/Telogen Ratio- Change in anagen/telogen ratio monthly from baseline to 6 months . Patient-Reported Outcomes- Changes in patient-reported outcomes, such as hair growth satisfaction, hair loss severity, & quality of life. Safety Assessments- Incidence & severity of adverse events, such as injection site reactions, allergic reactions & hormonal changes. Timepoint: monthly | — |
Countries
India
Contacts
Public ContactDr Varsha Jamale
Krishna Vishwa Vidyapeeth (Deemed to be University), Karad
Outcome results
None listed